NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

ACRS

NASDAQ:ACRSNASDAQ
1 announcements
Credibility Score100%
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Routineunclear

Aclaris' lead antibody failed Phase 2, shifting focus to other pipeline assets.

about 3 hours ago
▼